These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Therapeutic potential of anticancer immunotoxins. Choudhary S; Mathew M; Verma RS Drug Discov Today; 2011 Jun; 16(11-12):495-503. PubMed ID: 21511052 [TBL] [Abstract][Full Text] [Related]
4. [Recombinant immunotoxin for cancer therapy: current status and prospective]. Nagata S Tanpakushitsu Kakusan Koso; 2001 Mar; 46(4 Suppl):540-6. PubMed ID: 11268658 [No Abstract] [Full Text] [Related]
5. Cytotoxic immune responses mediated by monoclonal antibodies in MS: incorrectly dismissed as ineffective? Killestein J; Polman CH Int MS J; 2007 Jun; 14(2):39-40. PubMed ID: 17686340 [No Abstract] [Full Text] [Related]
6. Immunotoxins: status and prospects. Spooner RA; Lord JM Trends Biotechnol; 1990 Jul; 8(7):189-93. PubMed ID: 1366624 [TBL] [Abstract][Full Text] [Related]
12. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. Keppler-Hafkemeyer A; Kreitman RJ; Pastan I Int J Cancer; 2000 Jul; 87(1):86-94. PubMed ID: 10861457 [TBL] [Abstract][Full Text] [Related]
16. Immunotoxins: a clinical review of their use in the treatment of malignancies. Hertler AA; Frankel AE J Clin Oncol; 1989 Dec; 7(12):1932-42. PubMed ID: 2685183 [TBL] [Abstract][Full Text] [Related]
17. Targeted antibodies in the treatment of lymphomas. Falini B; Terenzi A; Liso A; Flenghi L; Solinas A; Pasqualucci L Cancer Surv; 1997; 30():295-309. PubMed ID: 9547998 [TBL] [Abstract][Full Text] [Related]
18. Technology evaluation: SGN-15, Seattle Genetics Inc. Smith S Curr Opin Mol Ther; 2001 Jun; 3(3):295-302. PubMed ID: 11497354 [TBL] [Abstract][Full Text] [Related]
19. Immunotoxins: current use and future prospects in bone marrow transplantation and cancer treatment. Neville DM Crit Rev Ther Drug Carrier Syst; 1986; 2(4):329-52. PubMed ID: 3549005 [TBL] [Abstract][Full Text] [Related]